TABLE OF CONTENTS.

SEC. 2. TABLE OF CONTENTS. The table of contents for this division is as follows: DIVISION F—FDA USER FEE REAUTHORIZATION ACT OF 2022 Sec. 1. Short title. Sec. 2. Table of contents. TITLE I—FEES RELATING TO DRUGS Sec. 1001. Short title; finding. Sec. 1002. Definitions. Sec. 1003. Authority to assess and use drug fees. Sec. 1004. Reauthorization; reporting requirements. Sec. 1005. Sunset dates. Sec. 1006. Effective date. Sec. 1007. Savings clause. TITLE II—FEES RELATING TO DEVICES Sec. 2001. Short title; finding. Sec. 2002. Definitions. Sec. 2003. Authority to assess and use device fees. Sec. 2004. Reauthorization; reporting requirements. Sec. 2005. Conformity assessment pilot program. Sec. 2006. Reauthorization of third-party review program. Sec. 2007. Sunset dates. Sec. 2008. Effective date. Sec. 2009. Savings clause. TITLE III—FEES RELATING TO GENERIC DRUGS Sec. 3001. Short title; finding. Sec. 3002. Authority to assess and use human generic drug fees. Sec. 3003. Reauthorization; reporting requirements. Sec. 3004. Sunset dates. Sec. 3005. Effective date. Sec. 3006. Savings clause. TITLE IV—FEES RELATING TO BIOSIMILAR BIOLOGICAL PRODUCTS Sec. 4001. Short title; finding. Sec. 4002. Definitions. Sec. 4003. Authority to assess and use biosimilar biological product fees. Sec. 4004. Reauthorization; reporting requirements. Sec. 4005. Sunset dates. Sec. 4006. Effective date. Sec. 4007. Savings clause. TITLE V—REAUTHORIZATION OF OTHER PROVISIONS Sec. 5001. Reauthorization of the best pharmaceuticals for children program. Sec. 5002. Reauthorization of the humanitarian device exemption incentive. Sec. 5003. Reauthorization of the pediatric device consortia program. Sec. 5004. Reauthorization of provision pertaining to drugs containing single enantiomers. Sec. 5005. Reauthorization of the critical path public-private partnership. Sec. 5006. Reauthorization of orphan drug grants. Sec. 5007. Reauthorization of certain device inspections. Sec. 5008. Reauthorization of reporting requirements related to pending generic drug applications and priority review applications.